GH Research PLC (GHRS) PT Raised at RBC Capital Following Psychedelics Symposium

RBC Capital analyst Brian Abrahams raised the price target on GH Research PLC (NASDAQ: GHRS) to $40.00 (from $33.00) while maintaining an Outperform rating.

The analyst commented: "Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform; Following our Psychedelics Symposium and discussions with mgmt, payers, and docs, we are increasingly optimistic on GHRS's longterm sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality midstage story in the emerging psychedelics space."

You May Also Be Interested In

• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities